Search

Displaying results 3731 - 3740 of 7603 in total
  1. Drug

    Methoxyphenamine

    go.drugbank.com/drugs/DB13624
    Approved

    Categories: Adrenergics for Systemic Use, Drugs for Obstructive Airway Diseases
  2. Drug

    Pancuronium

    go.drugbank.com/drugs/DB01337
    Approved

    A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.

  3. Drug

    Pipecuronium

    go.drugbank.com/drugs/DB01338
    ApprovedInvestigationalWithdrawn

    Pipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.

  4. Drug

    Firocoxib

    go.drugbank.com/drugs/DB09217
    ExperimentalVet approved

    Food and Drug Administration for horses. Firocoxib is not intended or approved for use in human medicine. … It currently approved for veterinary use in dogs and horses under the brand names Equioxx and Previcox. Firocoxib was the first COX-2 inhibitor approved by the U.S.

  5. Drug

    Patritumab deruxtecan

    go.drugbank.com/drugs/DB21996
    Investigational

    Patritumab deruxtecan is under investigation in clinical trial NCT06596694 (Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)).

    Synonyms: Anti-her3 antibody-drug conjugate u3 1402
  6. Drug

    Antrafenine

    go.drugbank.com/drugs/DB01419
    Approved

    Antrafenine is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen. It is not widely used as it has largely been replaced by newer drugs.

  7. Drug

    Prezatide copper

    go.drugbank.com/drugs/DB14683
    Investigational

    Prezatide is used in cosmetic products for the skin and hair.

  8. Drug

    Lonaprisan

    go.drugbank.com/drugs/DB16221
    Investigational

    Lonaprisan is under investigation in clinical trial NCT00555919 (ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer).

  9. Drug

    MK-4830

    go.drugbank.com/drugs/DB17454
    Investigational

    MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.

  10. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders.